BioSpace News Archive

Drug Development

J&J Gets Phase II Win for First Targeted Oral Peptide in Plaque Psoriasis

Johnson & Johnson’s Protagonist-partnered oral psoriasis candidate was able to sustain its therapeutic benefit through one year, according to data presented on Saturday at the American Academy of Dermatology annual meeting.

March 11, 2024
·
2 min read
·
Tristan Manalac
Policy

FDA Rejects Viatris, Mapi’s Long-Acting Multiple Sclerosis Injection

With Monday’s FDA rejection of their long-acting glatiramer acetate formulation, Viatris and Mapi Pharma continue the biopharma industry’s recent losing streak in multiple sclerosis.

March 11, 2024
·
2 min read
·
Tristan Manalac
Business

Innovent Biologics Closes ADC-Focused Maryland Site, Lays Off Researchers

The Chinese biopharma company will be closing its U.S. headquarters and wet lab in the D.C. suburbs, according to scientists who recently lost their jobs.

March 11, 2024
·
1 min read
·
Neil Versel
Business

Boehringer, Sosei Ink Potential $732M Deal for Schizophrenia Treatment

Boehringer Ingelheim has paid $27.3 million upfront to Sosei Heptares to develop a small molecule agonist of GPR52 to treat the positive, negative and cognitive symptoms of schizophrenia.

March 11, 2024
·
2 min read
·
Tyler Patchen
Drug Development

Alumis’ TYK2 Blocker Clears Phase II in Plaque Psoriasis on Heels of Series C

Fresh off its $259 million Series C funding round, Alumis unveiled mid-stage data Saturday for its TYK2 inhibitor ESK-001 demonstrating strong symptomatic improvement in moderate-to-severe plaque psoriasis.

March 11, 2024
·
2 min read
·
Tristan Manalac
Business

Alkermes and Jazz: Two Different Approaches to Neuroscience, Oncology Portfolios

Alkermes spun off its oncology business in late 2023 to become a pure-play neuroscience company, while Jazz Pharmaceuticals continues to invest in and focus on both of its businesses.

March 11, 2024
·
3 min read
·
Greg Slabodkin
Drug Development

Novartis’ Remibrutinib Shows Promise in Small Mid-Stage Hidradenitis Suppurativa Study

Early Phase IIb data from 66 patients showed Novartis’ BTK inhibitor remibrutinib has potential outside chronic spontaneous urticaria, leading to symptomatic relief in patients with hidradenitis suppurativa.

March 11, 2024
·
2 min read
·
Tristan Manalac
Drug Development

Incyte Gets Phase II Win, Targets Blockbuster Dupixent in Skin Disease

Incyte’s povorcitinib met both primary and secondary endpoints to relieve itching and improve skin clearance by 16 weeks, suggesting efficacy that is competitive with Sanofi and Regeneron’s blockbuster Dupixent.

March 11, 2024
·
2 min read
·
Kate Goodwin
Policy

ONWARD® Medical Accepted to New US FDA TAP Program for Development of its ARC-BCI™ System

ONWARD Medical N.V. announces that it has been accepted into the US FDA’s new Total Product Lifecycle Advisory Program for its brain-computer interface technology.

March 11, 2024
·
5 min read
Business

Fortrea Reports Fourth Quarter and Full-Year 2023 Results; Issues Full-Year 2024 Guidance

Fortrea, a leading global contract research organization, reported financial results for the fourth quarter and full year ended December 31, 2023.

March 11, 2024
·
19 min read